Metenolone enanthate

(Redirected from Methenolone enanthate)
Jump to: navigation, search
Metenolone enanthate
Metenolone enanthate.png
Pharmacokinetic data
Elimination half-life10.5 days
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC27H42O3
Molar mass414.621 g/mol

WikiDoc Resources for Metenolone enanthate

Articles

Most recent articles on Metenolone enanthate

Most cited articles on Metenolone enanthate

Review articles on Metenolone enanthate

Articles on Metenolone enanthate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Metenolone enanthate

Images of Metenolone enanthate

Photos of Metenolone enanthate

Podcasts & MP3s on Metenolone enanthate

Videos on Metenolone enanthate

Evidence Based Medicine

Cochrane Collaboration on Metenolone enanthate

Bandolier on Metenolone enanthate

TRIP on Metenolone enanthate

Clinical Trials

Ongoing Trials on Metenolone enanthate at Clinical Trials.gov

Trial results on Metenolone enanthate

Clinical Trials on Metenolone enanthate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Metenolone enanthate

NICE Guidance on Metenolone enanthate

NHS PRODIGY Guidance

FDA on Metenolone enanthate

CDC on Metenolone enanthate

Books

Books on Metenolone enanthate

News

Metenolone enanthate in the news

Be alerted to news on Metenolone enanthate

News trends on Metenolone enanthate

Commentary

Blogs on Metenolone enanthate

Definitions

Definitions of Metenolone enanthate

Patient Resources / Community

Patient resources on Metenolone enanthate

Discussion groups on Metenolone enanthate

Patient Handouts on Metenolone enanthate

Directions to Hospitals Treating Metenolone enanthate

Risk calculators and risk factors for Metenolone enanthate

Healthcare Provider Resources

Symptoms of Metenolone enanthate

Causes & Risk Factors for Metenolone enanthate

Diagnostic studies for Metenolone enanthate

Treatment of Metenolone enanthate

Continuing Medical Education (CME)

CME Programs on Metenolone enanthate

International

Metenolone enanthate en Espanol

Metenolone enanthate en Francais

Business

Metenolone enanthate in the Marketplace

Patents on Metenolone enanthate

Experimental / Informatics

List of terms related to Metenolone enanthate


Overview

Methenolone enanthate, or methenolone enanthate, is a dihydrotestosterone (DHT) based anabolic steroid. It is an ester derivative of methenolone sold commonly under the brand names Primobolan (tablet form) or Primobolan Depot (injectable).

When it interacts with the aromatase enzyme it does not form any estrogens. It is used by people who are very susceptible to estrogenic side effects, having lower estrogenic properties than nandrolone. Methenolone, in form of enanthate and acetate, is available as an injection or as an oral respectively. The injection is naturally regarded as having a higher bioavailability. It is an enanthate ester which is quite long-acting. Because it by-passes hepatic breakdown on the first pass, it also has a higher survival rate. The tablets are in a short-lived acetate form. Methenolone is not 17-alpha-alkylated, but 1-methylated for oral bioavailability. This reduces the stress on the liver, but also the availability. It is considered one of the safer steroids, meaning it has few side effects. Methenolone has no estrogenic side effects, and its effects on cholesterol levels are minimal. In doses of 200 mg or less (intramuscular) blood pressure is rarely altered.

It is possibly one of the safer anabolic steroids for females due to very low virilization effects in short-term usage. Of course, this is not a blanket-statement and individual results (dependent on doses and tolereance) will vary.

Methenolone is also not overly suppressive of the HPTA axis, although how suppressive is debatable. For this reason, many bodybuilders use it in between steroid cycles during their "off-time" to help maintain their gains and strength. The long term safety of such a practice possibly dangerous and can lead to permanent suppression of the HPTA.

References




Linked-in.jpg